ArticleBMC gastroenterology2026
Computed tomography imaging features aid in identifying cirrhotic patients with poor response to endoscopic therapy for gastroesophageal variceal hemorrhage.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate whether computed tomography (CT) imaging features can aid in identifying cirrhotic patients with poor response to endoscopic therapy for gastroesophageal variceal hemorrhage (GVH).
methodsCirrhotic patients with a history of endoscopic therapy for GVH were retrospectively enrolled (n = 158). Pre-endoscopic data, hepatic venous pressure gradient (HVPG), and endoscopic and CT imaging data were collected and analyzed. The cross-sectional area of skeletal muscle (SMA) at the level of the third lumbar vertebra was measured, and the skeletal muscle index (SMI) was calculated by dividing SMA by the square of the patient's height. Spleen volume was measured using a semi-automatic segmentation tool.
resultsHVPG > 16 mmHg (p = 0.033), SMI-related sarcopenia (p < 0.001), and significant splenomegaly (defined as spleen volume ≥ 974.3 cm³, p = 0.008) were identified as independent risk factors for variceal rebleeding after endoscopic therapy in these cirrhotic patients. The cumulative risk curve showed a higher probability of rebleeding in the sarcopenia group (p < 0.001). Similarly, the rebleeding rate was significantly higher in the HVPG > 16mmHg group compared to the HVPG ≤ 16mmHg group (p = 0.029). And patients with significant splenomegaly demonstrated a significantly higher rebleeding probability (p = 0.021).
conclusionCT imaging features, particularly SMI-related sarcopenia and significant splenomegaly, in combination with HVPG, are risk factors associated with gastroesophageal variceal rebleeding after endoscopic therapy. Early identification of cirrhotic patients with poor response to endoscopic therapy is crucial for implementing more aggressive interventions to prevent variceal rebleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.